Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer

Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer

Conventional treatment of prostate cancer (PCa) uses androgen-deprivation therapy (ADT) to inhibit androgen receptor (AR) signaling-driven tumor progression. ADT-induced PCa recurrence may progress to an AR-negative phenotype with neuroendocrine (NE) histologic features, which are associated with me...

Full description

Bibliographic Details
Main Authors: Wei-Yu Chen, Phan Vu Thuy Dung, Hsiu-Lien Yeh, Wei-Hao Chen, Kuo-Ching Jiang, Han-Ru Li, Zi-Qing Chen, Michael Hsiao, Jiaoti Huang, Yu-Ching Wen, Yen-Nien Liu
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Redox Biology
Subjects:
Androgen deprivation therapy (ADT)
Neuroendocrine prostate cancer (NEPC)
Pyruvate kinase L/R (PKLR)
Reactive oxygen species modulator 1 (ROMO1)
MYCN proto-oncogene (MYCN)
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231723000873

Internet

http://www.sciencedirect.com/science/article/pii/S2213231723000873

Similar Items